Systematic treatment of HHT patients with the humanized anti-VEGF antibody (bevacizumab, 5–10 mg/kg) have shown improvement in the frequency of epistaxis, the number of required transfusion and improved liver function in patients with severe phenotype (Ardelean and Letarte, 2015). This evidence concerns the gene VEGFA and hereditary hemorrhagic telangiectasia.